Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis

Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase.
The stages identify tumours that have a similar prognosis and thus are treated in a similar way. Patients with lower stage numbers tend to have a better prognosis. Stage I. T1, N0, M0: Mesothelioma involves either the right or left pleura lining the chest wall or diaphragm.

Mesothelioma is a type of cancer that typically occurs due to exposure to asbestos. A mesothelioma prognosis depends on the stage of the disease and the age of the patient. Of the four types of mesothelioma, pleural malignant mesothelioma is the most common.

A malignant (cancerous) tumour of the mesothelium is called a malignant mesothelioma. As most mesothelial tumours are cancerous, malignant mesothelioma is often simply called mesothelioma. This type has the best prognosis (outlook for survival). The other two types are the sarcomatoid type (7%-20%), and the mixed/biphasic type (20%-35%). Malignant pleural mesothelioma (MPM) is a disease with a very dismal prognosis. A median survival of 6-18 months is expected in most patients.